<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075267</url>
  </required_header>
  <id_info>
    <org_study_id>PT010010</org_study_id>
    <nct_id>NCT03075267</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of&#xD;
      PT003 in healthy Chinese adult subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, Double-Blind, Parallel Group, Study to Assess the Pharmacokinetics and&#xD;
      Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects&#xD;
      Following a Single Administration and After Chronic Administration for 7 Days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Budesonide</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Budesonide Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Glycopyrronium</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) - Formoterol</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) of Formoterol Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</measure>
    <time_frame>Day 8</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</measure>
    <time_frame>Day 8</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</measure>
    <time_frame>Day 8</time_frame>
    <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Budesonide</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Budesonide Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) - Formoterol</measure>
    <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Time to maximum plasma concentration (tmax) - Formoterol Day 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Budesonide</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Glycopyrronium</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Formoterol</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Budesonide</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Glycopyrronium</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Formoterol</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t½) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Elimination half-life (t½) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t½) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Elimination half-life (t½) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t½) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Elimination half-life (t½) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent total body clearance (CL/F) - Budesonide Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent total body clearance (CL/F) - Glycopyrronium Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent total body clearance (CL/F) - Formoterol Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent volume of distribution (Vd/F) - Budesonide - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent volume of distribution (Vd/F) - Glycopyrronium - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Apparent volume of distribution (Vd/F) - Formoterol - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (λz) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Terminal elimination rate constant (λz) - Budesonide - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (λz) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Terminal elimination rate constant (λz) - Glycopyrronium - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (λz) - Formoterol</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Terminal elimination rate constant (λz) - Formoterol - Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for Cmax (RAC [Cmax]) - Budesonide</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Accumulation ratio for Cmax (RAC [Cmax]) - Budesonide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for Cmax (RAC [Cmax]) - Glycopyrronium</measure>
    <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
    <description>Accumulation ratio for Cmax (RAC [Cmax]) - Glycopyrronium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for Cmax (RAC [Cmax]) - Formoterol</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Accumulation ratio for Cmax (RAC [Cmax]) - Formoterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Exam Findings</measure>
    <time_frame>Visit 4, Day 8</time_frame>
    <description>Number of subjects with clinically significant changes in post baseline physical exam findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Tests</measure>
    <time_frame>Visit 4, Day 8</time_frame>
    <description>Number of subjects with clinically significant changes in post baseline laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Visit 4, Day 8</time_frame>
    <description>Number of subjects with clinically significant changes in post baseline electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events/Adverse Events</measure>
    <time_frame>Visit 4, Day 8</time_frame>
    <description>Number of subjects with clinically significant changes in post baseline serious TEAEs (treatment-emergent adverse events) or TEAEs leading to withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Visit 4, Day 8</time_frame>
    <description>Number of subjects with clinically significant changes in post baseline vital signs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT010 (BGF MDI) 320/14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT010 (BGF MDI) 160/14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT010 (BGF MDI) 160/14.4/9.6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (GFF MDI) 14.4/9.6 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 (GFF MDI) 14.4/9.6 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT010 (BGF MDI) 320/14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT010 (BGF MDI) 320/14.4/9.6 µg</arm_group_label>
    <other_name>Budesonide, Glycopyrronium, Formoterol Metered Dose Inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT010 (BGF MDI) 160/14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT010 (BGF MDI) 160/14.4/9.6 µg</arm_group_label>
    <other_name>Budesonide, Glycopyrronium, Formoterol Metered Dose Inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003 (GFF MDI) 14.4/9.6 µg</intervention_name>
    <description>A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.</description>
    <arm_group_label>PT003 (GFF MDI) 14.4/9.6 µg</arm_group_label>
    <other_name>Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female Chinese subjects 18-45 years of age&#xD;
&#xD;
          -  Females of childbearing potential must agree to be abstinent or else use one of the&#xD;
             medically acceptable forms of contraception A female whose male partner has had a&#xD;
             vasectomy must agree to use one additional form of medically acceptable contraception.&#xD;
&#xD;
        A male subject with female partner of child bearing potential must agree to use one&#xD;
        additional form of medically acceptable contraception&#xD;
&#xD;
        -Be in good general health as assessed at Screening and have no clinically significant&#xD;
        abnormal labs at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing female subjects or subjects who are trying to conceive&#xD;
&#xD;
          -  Subjects with clinically significant neurologic, cardiovascular, hepatic, renal,&#xD;
             endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that&#xD;
             would interfere with participation in this study&#xD;
&#xD;
          -  Subjects with a history of ECG abnormalities&#xD;
&#xD;
          -  Subjects who have cancer that has not been in complete remission for at least 5 years&#xD;
&#xD;
          -  Male subjects with symptomatic prostatic hypertrophy that is clinically significant in&#xD;
             the opinion of the Investigator&#xD;
&#xD;
          -  Male subjects with a trans-urethral resection of the prostate or full resection of the&#xD;
             prostate within 6 months prior to Screening&#xD;
&#xD;
          -  Males with bladder neck obstruction or urinary retention that is clinically&#xD;
             significant in the opinion of the Investigator&#xD;
&#xD;
          -  Subjects with a diagnosis of glaucoma that in the opinion of the Investigator has not&#xD;
             been adequately treated&#xD;
&#xD;
          -  History of substance-related disorders within 1 year of Screening&#xD;
&#xD;
          -  History of smoking or the use of nicotine containing products or electronic cigarettes&#xD;
             within 3 months of Screening by self-reporting&#xD;
&#xD;
          -  A positive alcohol breathalyzer or urine drug screen for drugs of abuse at the&#xD;
             Screening Visit or at the beginning of each inpatient period&#xD;
&#xD;
          -  Treatment with any prescription or non-prescription drugs (including vitamins, herbal,&#xD;
             and dietary supplements) within 30 days&#xD;
&#xD;
          -  Positivity for human immunodeficiency virus (HIV) or Hepatitis B surface antigen&#xD;
             (HbsAg) or positive hepatitis C antibody at Screening&#xD;
&#xD;
          -  Positive for Syphilis Antibody&#xD;
&#xD;
          -  Subjects with any flu-like syndrome or other respiratory infections&#xD;
&#xD;
          -  Recently vaccinated with an attenuated live virus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M. Dorinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=PT010010&amp;amp;attachmentIdentifier=655b9508-3a4c-48cb-835e-ad569131ecb6&amp;amp;fileName=PT010010-03_China_PK_CSP_v4.0_Redacted-PDF-A.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=PT010010&amp;amp;attachmentIdentifier=aff556d3-330c-4fa8-af1a-1fd3f266eb35&amp;amp;fileName=PT010010_SAP_v1.0_2017-08-24_Redacted-PDF-A.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>December 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 19, 2021</results_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03075267/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03075267/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single site in China.</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 1:1:1 ratio to 1 of 3 treatments: BGF MDI 320/14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, or GFF MDI 14.4/9.6 μg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
        </group>
        <group group_id="P2">
          <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
        </group>
        <group group_id="P3">
          <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
          <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population - all subjects who received at least 1 dose of any blinded study drug</population>
      <group_list>
        <group group_id="B1">
          <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
        </group>
        <group group_id="B2">
          <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
        </group>
        <group group_id="B3">
          <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
          <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Demographics</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="3.8"/>
                    <measurement group_id="B2" value="26.9" spread="5.1"/>
                    <measurement group_id="B3" value="24.7" spread="4.1"/>
                    <measurement group_id="B4" value="25.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Chinese subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>Non Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.99" spread="5.29"/>
                    <measurement group_id="B2" value="60.00" spread="6.13"/>
                    <measurement group_id="B3" value="62.75" spread="5.31"/>
                    <measurement group_id="B4" value="60.91" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="1.4"/>
                    <measurement group_id="B2" value="21.6" spread="1.2"/>
                    <measurement group_id="B3" value="21.9" spread="1.1"/>
                    <measurement group_id="B4" value="21.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Budesonide</title>
        <description>Maximum plasma concentration (Cmax) of Budesonide Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Budesonide</title>
          <description>Maximum plasma concentration (Cmax) of Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.308" spread="67.6"/>
                    <measurement group_id="O2" value="224.298" spread="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Budesonide</title>
        <description>Maximum plasma concentration (Cmax) of Budesonide Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Budesonide</title>
          <description>Maximum plasma concentration (Cmax) of Budesonide Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="626.435" spread="78.1"/>
                    <measurement group_id="O2" value="315.425" spread="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Glycopyrronium</title>
        <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Glycopyrronium</title>
          <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.884" spread="92.5"/>
                    <measurement group_id="O2" value="5.286" spread="120.8"/>
                    <measurement group_id="O3" value="5.674" spread="113.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Glycopyrronium</title>
        <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Glycopyrronium</title>
          <description>Maximum plasma concentration (Cmax) of Glycopyrronium Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.303" spread="96.9"/>
                    <measurement group_id="O2" value="11.754" spread="103.0"/>
                    <measurement group_id="O3" value="13.124" spread="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Formoterol</title>
        <description>Maximum plasma concentration (Cmax) of Formoterol Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Formoterol</title>
          <description>Maximum plasma concentration (Cmax) of Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.651" spread="55.8"/>
                    <measurement group_id="O2" value="9.932" spread="71.9"/>
                    <measurement group_id="O3" value="10.618" spread="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) - Formoterol</title>
        <description>Maximum plasma concentration (Cmax) of Formoterol Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) - Formoterol</title>
          <description>Maximum plasma concentration (Cmax) of Formoterol Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.125" spread="59.1"/>
                    <measurement group_id="O2" value="16.945" spread="54.5"/>
                    <measurement group_id="O3" value="17.710" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1747.910" spread="43.5"/>
                    <measurement group_id="O2" value="811.812" spread="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Budesonide</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Budesonide Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2509.888" spread="53.4"/>
                    <measurement group_id="O2" value="1249.615" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.400" spread="23.5"/>
                    <measurement group_id="O2" value="27.197" spread="41.3"/>
                    <measurement group_id="O3" value="29.002" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Glycopyrronium</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Glycopyrronium Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.487" spread="64.8"/>
                    <measurement group_id="O2" value="77.078" spread="47.5"/>
                    <measurement group_id="O3" value="72.636" spread="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.843" spread="35.0"/>
                    <measurement group_id="O2" value="46.492" spread="39.3"/>
                    <measurement group_id="O3" value="53.583" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</title>
        <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - Formoterol</title>
          <description>Area under the plasma concentration-time curve from 0-12 hours (AUC 0-12) - Formoterol Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.936" spread="39.5"/>
                    <measurement group_id="O2" value="85.322" spread="34.0"/>
                    <measurement group_id="O3" value="83.499" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Budesonide</title>
        <description>Time to maximum plasma concentration (tmax) - Budesonide Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Budesonide</title>
          <description>Time to maximum plasma concentration (tmax) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.333" lower_limit="0.10" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Budesonide</title>
        <description>Time to maximum plasma concentration (tmax) - Budesonide Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Budesonide</title>
          <description>Time to maximum plasma concentration (tmax) - Budesonide Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" lower_limit="0.10" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.333" lower_limit="0.03" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</title>
        <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</title>
          <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" lower_limit="0.03" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.100" lower_limit="0.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.100" lower_limit="0.03" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</title>
        <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Glycopyrronium</title>
          <description>Time to maximum plasma concentration (tmax) - Glycopyrronium Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" lower_limit="0.03" upper_limit="4.00"/>
                    <measurement group_id="O2" value="0.333" lower_limit="0.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.333" lower_limit="0.03" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Formoterol</title>
        <description>Time to maximum plasma concentration (tmax) - Formoterol Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Formoterol</title>
          <description>Time to maximum plasma concentration (tmax) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.833" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.100" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.100" lower_limit="0.10" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) - Formoterol</title>
        <description>Time to maximum plasma concentration (tmax) - Formoterol Day 8</description>
        <time_frame>Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) - Formoterol</title>
          <description>Time to maximum plasma concentration (tmax) - Formoterol Day 8</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.100" lower_limit="0.10" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.100" lower_limit="0.10" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Budesonide</title>
        <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Budesonide Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Budesonide</title>
          <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1884.912" spread="43.5"/>
                    <measurement group_id="O2" value="830.012" spread="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Glycopyrronium</title>
        <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Glycopyrronium Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Glycopyrronium</title>
          <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.616" spread="89.8"/>
                    <measurement group_id="O2" value="17.707" spread="111.2"/>
                    <measurement group_id="O3" value="20.287" spread="103.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Formoterol</title>
        <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Formoterol Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - Formoterol</title>
          <description>Area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration (AUC 0-t) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.326" spread="41.4"/>
                    <measurement group_id="O2" value="47.408" spread="48.2"/>
                    <measurement group_id="O3" value="45.950" spread="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Budesonide</title>
        <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Budesonide Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Budesonide</title>
          <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1936.211" spread="42.0"/>
                    <measurement group_id="O2" value="876.673" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Glycopyrronium</title>
        <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Glycopyrronium Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Glycopyrronium</title>
          <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.465" spread="19.6"/>
                    <measurement group_id="O2" value="33.014" spread="NA">value assessed on only one patient - no coefficient of variation</measurement>
                    <measurement group_id="O3" value="43.537" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Formoterol</title>
        <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Formoterol Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - Formoterol</title>
          <description>Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC 0-∞) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.617" spread="37.5"/>
                    <measurement group_id="O2" value="73.123" spread="40.5"/>
                    <measurement group_id="O3" value="70.608" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t½) - Budesonide</title>
        <description>Elimination half-life (t½) - Budesonide Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t½) - Budesonide</title>
          <description>Elimination half-life (t½) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.572" spread="25.3"/>
                    <measurement group_id="O2" value="3.168" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t½) - Glycopyrronium</title>
        <description>Elimination half-life (t½) - Glycopyrronium Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t½) - Glycopyrronium</title>
          <description>Elimination half-life (t½) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.676" spread="52.5"/>
                    <measurement group_id="O2" value="8.539" spread="161.3"/>
                    <measurement group_id="O3" value="6.194" spread="108.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t½) - Formoterol</title>
        <description>Elimination half-life (t½) - Formoterol Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t½) - Formoterol</title>
          <description>Elimination half-life (t½) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.098" spread="22.7"/>
                    <measurement group_id="O2" value="5.657" spread="38.1"/>
                    <measurement group_id="O3" value="5.628" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) - Budesonide</title>
        <description>Apparent total body clearance (CL/F) - Budesonide Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) - Budesonide</title>
          <description>Apparent total body clearance (CL/F) - Budesonide Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.271" spread="42.0"/>
                    <measurement group_id="O2" value="182.508" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) - Glycopyrronium</title>
        <description>Apparent total body clearance (CL/F) - Glycopyrronium Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) - Glycopyrronium</title>
          <description>Apparent total body clearance (CL/F) - Glycopyrronium Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.038" spread="19.6"/>
                    <measurement group_id="O2" value="436.184" spread="NA">value assessed on only one patient - no coefficient of variation</measurement>
                    <measurement group_id="O3" value="330.757" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/F) - Formoterol</title>
        <description>Apparent total body clearance (CL/F) - Formoterol Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) - Formoterol</title>
          <description>Apparent total body clearance (CL/F) - Formoterol Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.801" spread="37.5"/>
                    <measurement group_id="O2" value="131.286" spread="40.5"/>
                    <measurement group_id="O3" value="135.962" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) - Budesonide</title>
        <description>Apparent volume of distribution (Vd/F) - Budesonide - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) - Budesonide</title>
          <description>Apparent volume of distribution (Vd/F) - Budesonide - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090.237" spread="43.0"/>
                    <measurement group_id="O2" value="834.269" spread="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) - Glycopyrronium</title>
        <description>Apparent volume of distribution (Vd/F) - Glycopyrronium - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) - Glycopyrronium</title>
          <description>Apparent volume of distribution (Vd/F) - Glycopyrronium - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2172.038" spread="17.6"/>
                    <measurement group_id="O2" value="2123.999" spread="NA">value assessed on only one patient - no coefficient of variation</measurement>
                    <measurement group_id="O3" value="1864.314" spread="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/F) - Formoterol</title>
        <description>Apparent volume of distribution (Vd/F) - Formoterol - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F) - Formoterol</title>
          <description>Apparent volume of distribution (Vd/F) - Formoterol - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1125.215" spread="26.0"/>
                    <measurement group_id="O2" value="1000.172" spread="29.2"/>
                    <measurement group_id="O3" value="1035.257" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Rate Constant (λz) - Budesonide</title>
        <description>Terminal elimination rate constant (λz) - Budesonide - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz) - Budesonide</title>
          <description>Terminal elimination rate constant (λz) - Budesonide - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" spread="25.3"/>
                    <measurement group_id="O2" value="0.219" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Rate Constant (λz) - Glycopyrronium</title>
        <description>Terminal elimination rate constant (λz) - Glycopyrronium - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz) - Glycopyrronium</title>
          <description>Terminal elimination rate constant (λz) - Glycopyrronium - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" spread="52.5"/>
                    <measurement group_id="O2" value="0.081" spread="161.3"/>
                    <measurement group_id="O3" value="0.112" spread="108.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Rate Constant (λz) - Formoterol</title>
        <description>Terminal elimination rate constant (λz) - Formoterol - Day 1</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (λz) - Formoterol</title>
          <description>Terminal elimination rate constant (λz) - Formoterol - Day 1</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136" spread="22.7"/>
                    <measurement group_id="O2" value="0.123" spread="38.1"/>
                    <measurement group_id="O3" value="0.123" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Budesonide</title>
        <description>Accumulation ratio for Cmax (RAC [Cmax]) - Budesonide</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Budesonide</title>
          <description>Accumulation ratio for Cmax (RAC [Cmax]) - Budesonide</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.400" spread="71.4"/>
                    <measurement group_id="O2" value="1.406" spread="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Glycopyrronium</title>
        <description>Accumulation ratio for Cmax (RAC [Cmax]) - Glycopyrronium</description>
        <time_frame>Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Glycopyrronium</title>
          <description>Accumulation ratio for Cmax (RAC [Cmax]) - Glycopyrronium</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.383" spread="86.4"/>
                    <measurement group_id="O2" value="2.319" spread="90.3"/>
                    <measurement group_id="O3" value="2.412" spread="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Formoterol</title>
        <description>Accumulation ratio for Cmax (RAC [Cmax]) - Formoterol</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for Cmax (RAC [Cmax]) - Formoterol</title>
          <description>Accumulation ratio for Cmax (RAC [Cmax]) - Formoterol</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.678" spread="50.1"/>
                    <measurement group_id="O2" value="1.706" spread="42.1"/>
                    <measurement group_id="O3" value="1.668" spread="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</title>
        <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</title>
          <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Budesonide</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.455" spread="45.9"/>
                    <measurement group_id="O2" value="1.539" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</title>
        <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</title>
          <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Glycopyrronium</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.324" spread="47.5"/>
                    <measurement group_id="O2" value="3.030" spread="43.0"/>
                    <measurement group_id="O3" value="3.189" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</title>
        <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</title>
          <description>Accumulation ratio for AUC 0-12 (RAC [AUC 0-12]) - Formoterol</description>
          <population>PK Population - defined as all subjects in the Safety Population who had sufficient data to reliably calculate at least 1 PK parameter and did not have a major protocol deviation</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.718" spread="28.7"/>
                    <measurement group_id="O2" value="1.835" spread="26.2"/>
                    <measurement group_id="O3" value="1.620" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Exam Findings</title>
        <description>Number of subjects with clinically significant changes in post baseline physical exam findings</description>
        <time_frame>Visit 4, Day 8</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Exam Findings</title>
          <description>Number of subjects with clinically significant changes in post baseline physical exam findings</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Significant Findings</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Tests</title>
        <description>Number of subjects with clinically significant changes in post baseline laboratory tests</description>
        <time_frame>Visit 4, Day 8</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Tests</title>
          <description>Number of subjects with clinically significant changes in post baseline laboratory tests</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Potassium</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram</title>
        <description>Number of subjects with clinically significant changes in post baseline electrocardiogram</description>
        <time_frame>Visit 4, Day 8</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram</title>
          <description>Number of subjects with clinically significant changes in post baseline electrocardiogram</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Significant electrocardiogram changes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events/Adverse Events</title>
        <description>Number of subjects with clinically significant changes in post baseline serious TEAEs (treatment-emergent adverse events) or TEAEs leading to withdrawal</description>
        <time_frame>Visit 4, Day 8</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events/Adverse Events</title>
          <description>Number of subjects with clinically significant changes in post baseline serious TEAEs (treatment-emergent adverse events) or TEAEs leading to withdrawal</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Serious TEAEs/TEAEs leading to withdrawal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs</title>
        <description>Number of subjects with clinically significant changes in post baseline vital signs</description>
        <time_frame>Visit 4, Day 8</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
          </group>
          <group group_id="O2">
            <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
            <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
          </group>
          <group group_id="O3">
            <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
            <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs</title>
          <description>Number of subjects with clinically significant changes in post baseline vital signs</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bradycardia events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the first administration of study drug through the Final Telephone Follow-up.</time_frame>
      <desc>The Safety Population was defined as all subjects who receive at least one dose of any blinded study drug. Serious Adverse Events were collected from the first administration of study drug up to 14 days following the last dose of study drug administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>PT010 (BGF MDI) 320/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg</description>
        </group>
        <group group_id="E2">
          <title>PT010 (BGF MDI) 160/14.4/9.6 µg</title>
          <description>PT010 Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) 160/14.4/9.6 µg</description>
        </group>
        <group group_id="E3">
          <title>PT003 (GFF MDI) 14.4/9.6 µg</title>
          <description>PT003 Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) 14.4/9.6 µg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study site will have the opportunity to publish the results of the study, provided that the sponsor has had the opportunity to review and comment on the study site's proposed publication prior to its being submitted for publication with the prior advice of legal (intellectual property counsel) and with proper regard to the protection of subjects' identities.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pearl Therapeutics, Inc.</name_or_title>
      <organization>Pearl Therapeutics, Inc.</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

